Dorsomorphin (Compound C): Precision AMPK Inhibition in Metabolic Research

Principle Overview: Dual Pathway Modulation with Dorsomorphin

Dorsomorphin (Compound C) is a potent, cell-permeable, ATP-competitive inhibitor of AMP-activated protein kinase (AMPK) with a Ki of 109 nM, exhibiting high selectivity over closely related kinases (source: product_spec). By simultaneously inhibiting AMPK and bone morphogenetic protein (BMP) signaling—specifically Smad 1/5/8 phosphorylation—Dorsomorphin empowers researchers to dissect the distinct and intertwined roles of metabolic regulation, autophagy, and differentiation. This dual specificity is especially valuable for experiments targeting the inhibition of AMPK activity in hepatocytes, manipulation of autophagic flux, and modulation of iron metabolism.

APExBIO’s Dorsomorphin is supplied as a solid, insoluble in water and ethanol, but dissolves efficiently in DMSO with gentle warming and ultrasonic treatment, providing flexibility across a range of in vitro and in vivo applications. The compound’s precision and reversibility make it indispensable for dissecting the contribution of AMPK and BMP pathways in metabolic, cancer, and developmental biology models (source: thought_leadership).

Step-by-Step Workflow: Experimental Enhancements Using Dorsomorphin

Integrating Dorsomorphin into metabolic and differentiation assays requires careful planning and adherence to optimized protocols. Below is a stepwise framework for leveraging Dorsomorphin’s dual-inhibition capacity in cellular and animal models:

1. Compound Preparation: Dissolve Dorsomorphin (Compound C) in DMSO at ≥8.49 mg/mL using gentle warming (37°C) and ultrasonic agitation to ensure complete solubilization (source: product_spec).
2. Cellular Assays: For inhibition of AMPK activity in hepatocytes or cancer cell lines (e.g., HeLa, HT-29), dilute DMSO stock to a final working concentration ranging from 1–10 μM in culture medium, maintaining DMSO below 0.1% v/v to minimize cytotoxicity.
3. BMP Pathway Studies: In differentiation assays—such as osteogenesis from mesenchymal stem cells—add Dorsomorphin at 2–5 μM to block BMP4-induced SMAD phosphorylation and analyze downstream effects on gene expression and mineralization.
4. Animal Models: For in vivo modulation of iron metabolism or bone formation, administer Dorsomorphin via intraperitoneal injection at 5 mg/kg body weight in mice, monitoring dosing intervals and endpoints per protocol (source: thought_leadership).
5. Readout and Analysis: Quantify AMPK and ACC phosphorylation by Western blot, assess autophagic flux via LC3-II/I ratios, and evaluate Smad 1/5/8 phosphorylation status. For metabolic studies, measure lactate production or glucose uptake as functional endpoints.

Protocol Parameters

• AMPK inhibition assay | 5 μM Dorsomorphin (Compound C) | Hepatocyte or HeLa cell cultures | Ensures robust, reversible suppression of AMPK signaling as shown by decreased ACC phosphorylation (80% reduction) | product_spec
• BMP signaling inhibition | 2–5 μM Dorsomorphin | MSC-derived osteoblast differentiation cultures | Blocks BMP4-induced SMAD 1/5/8 phosphorylation, modulating downstream gene transcription | workflow_recommendation
• Compound dissolution | ≥8.49 mg/mL in DMSO, 37°C, 10 min sonication | Stock preparation for in vitro and in vivo use | Achieves full solubility for accurate dosing and reproducibility | product_spec

Key Innovation from the Reference Study

The reference article (O-GlcNAcylation mediates Wnt-stimulated bone formation by rewiring aerobic glycolysis) uncovers a critical mechanism whereby O-GlcNAcylation, driven by Wnt signaling, enhances osteoblastogenesis and accelerates bone formation by stabilizing PDK1 and increasing glycolytic flux. This metabolic rewiring positions glucose metabolism as a central regulator of bone anabolism, highlighting how signaling crosstalk shapes cell fate and tissue repair.

For experimentalists, the findings recommend integrating metabolic readouts (e.g., glucose uptake, lactate production) and post-translational modification assays (e.g., O-GlcNAcylation status) into BMP/Wnt pathway studies. By combining Dorsomorphin’s BMP4-Smad blockade with metabolic endpoints, researchers can dissect not only pathway-specific effects but also the downstream consequences on cellular energy homeostasis and differentiation capacity. This dual approach enables more nuanced exploration of anabolic therapies and metabolic modulation in bone and stem cell research.

Advanced Applications and Comparative Advantages

Dorsomorphin’s unique profile as both an ATP-competitive AMPK inhibitor and a BMP signaling inhibitor opens doors to diverse applications that extend beyond standard AMPK pathway inhibition:

• Autophagy Regulation: Dorsomorphin inhibits autophagic proteolysis, making it a valuable tool for dissecting nutrient-sensing and cell survival mechanisms in cancer and neurobiology models (source: article_complement).
• Iron Metabolism Modulation: By downregulating hepatic hepcidin gene transcription, Dorsomorphin elevates serum iron levels and can model iron overload or deficiency syndromes in mice, supporting translational research in anemia and metabolic disorders (source: article_extension).
• Stem Cell Fate Control: In human embryonic stem cell cultures, Dorsomorphin’s BMP inhibition supports neural induction and self-renewal, facilitating the generation of lineage-specific progenitors for regenerative medicine (source: article_extension).

Compared to single-pathway inhibitors, Dorsomorphin’s dual action allows researchers to interrogate pathway crosstalk, metabolic rewiring, and differentiation outcomes in a single experimental framework. This versatility is illustrated by its use in studies ranging from muscle atrophy—where AMPK/PINK1/Parkin-mediated mitophagy is pivotal—to stem cell neural induction and cancer metabolism.

Troubleshooting and Optimization Tips

• Solubility Challenges: Dorsomorphin is insoluble in water and ethanol. Always prepare stock solutions in DMSO at ≥8.49 mg/mL, using gentle warming (37°C) and 10 minutes of sonication. Avoid prolonged storage of stock solutions; prepare fresh aliquots for each experiment (source: product_spec).
• Cytotoxicity Risk: Keep final DMSO concentrations in cell cultures ≤0.1% v/v to minimize off-target effects. Perform titration experiments to optimize Dorsomorphin concentration for each cell type or assay.
• Pathway Specificity: To validate selective inhibition, include controls with pathway agonists (e.g., AICAR for AMPK activation, BMP4 for SMAD phosphorylation) and confirm Dorsomorphin’s effects via Western blot or reporter assays.
• Batch-to-Batch Consistency: Source Dorsomorphin (Compound C) exclusively from trusted suppliers such as APExBIO to ensure reproducibility and purity across experiments.
• End-Point Validation: For metabolic rewiring studies, supplement classical pathway readouts (e.g., phospho-ACC, LC3-II) with functional outputs such as lactate secretion and O-GlcNAcylation status, as inspired by the reference study.

Interlinked Resources: Context and Continuity

Multiple articles expand upon Dorsomorphin’s applications and strategic value:

• Dorsomorphin (Compound C): Precision Inhibition in Pathway Studies complements this guide by offering protocol insights and troubleshooting strategies for robust experimental control across cell and animal models.
• Strategic Dual-Pathway Inhibition with Dorsomorphin (Compound C) provides a mechanistic deep dive, especially in advanced translational models, and extends applications into neurobiology and metabolic disease.
• Dorsomorphin (Compound C): Unraveling Metabolic Rewiring complements the metabolic and stem cell differentiation focus, highlighting emergent mechanisms not covered in standard product pages.

Together, these resources create a comprehensive knowledge base that supports both novice and advanced users in leveraging Dorsomorphin’s full experimental potential.

Future Outlook: Implications and Evolving Research Directions

The integration of Dorsomorphin (Compound C) into metabolic and differentiation studies will remain central as research into pathway crosstalk and metabolic rewiring accelerates. The reference study’s demonstration of O-GlcNAcylation as a key regulator of Wnt-driven osteogenesis not only informs future assay design but also underscores the utility of pathway inhibitors like Dorsomorphin in dissecting the metabolic underpinnings of cell fate decisions (source: reference_study).

Looking forward, combining Dorsomorphin’s dual-inhibition capabilities with advanced metabolic and proteomic readouts promises to unlock new insights in bone biology, regenerative medicine, and metabolic disease. The continued development of assay platforms that integrate pathway inhibition, metabolic flux analysis, and post-translational modification profiling will further elevate the precision and translational relevance of bench research.

Dorsomorphin (Compound C) from APExBIO remains a cornerstone reagent for researchers seeking to navigate the complexities of metabolic signaling and differentiation, backed by a robust evidence base and advanced protocol support.